CureVac turns the page on COVID-19 and flu mRNA vaccine programs

9 January 2023

German biopharma company CureVac (Nasdaq: CVAC) saw its shares rise 24%, to $7.94 on Friday, after it announced positive preliminary data from ongoing Phase I clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology.

The vaccine candidates are being developed in collaboration with UK pharma major GSK (LSE: GSK), but the partners still lag behind rivals in the race to expand use of mRNA technology. In October 2021, CureVac announced that it was withdrawing its first vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA), after trial results fell short of the level required for statistical success.

The preliminary results generated by this broad technology approach showed that vaccine candidates using a modified second-generation mRNA backbone produced promising immunogenicity and reactogenicity profiles in both indications. Based on these preliminary data, development of modified mRNA COVID-19 and flu vaccine candidates will be advanced to the next stage of clinical testing in 2023.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK